The Principal Investigator for the study will be Professor Roger B. Cohen at the Fox Chase Cancer Center in Philadelphia, USA.
"This is an important step of the development of the TTS products. Clinical trials in the US create the best opportunities for a registration on the US market", says Sven Andréasson, President & CEO Active Biotech.
Lund 9 January, 2003
Active Biotech AB (publ)
Sven Andréasson
President & CEO
Background
TTS stands for "Tumour Targeted Superantigens". The collective term "superantigens" refers to several different substances that include some of the most powerful known stimulators of the human immune system's T-cells, which are the body's strongest weapon in the arsenal it uses to kill unwanted cells. By aiming the superantigen at tumour cells via a tumour-specific antibody, Active Biotech has created a unique product that will recognise cancer cells and stimulate the body's own immune system to attack and kill them. In principle, TTS technology can be used to treat several different types of cancer, although Active Biotech has chosen to focus its development work on the treatment of lung cancer, renal cancer and pancreatic cancer.
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases (SAIK), as well as a novel concept for use in cancer immunotherapy (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
e-mail info@activebiotech.com